OBJECTIVE: To determine the relationship between mortality risk and the CD4 cell response to antiretroviral therapy (ART). DESIGN: Observational community-based ART cohort in South Africa. METHODS: CD4 cell counts were measured 4 monthly, and deaths were prospectively ascertained. Cumulative person-time accrued within a range of updated CD4 cell count strata (CD4 cell-strata) was calculated and used to derive CD4 cell-stratified mortality rates. RESULTS: Patients (2423) (median baseline CD4 cell count of 105 cells/microl) were observed for up to 5 years of ART. One hundred and ninety-seven patients died during 3155 person-years of observation. In microltivariate analysis, mortality rate ratios associated with 0-49, 50-99, 100-199, 200-299, 300-399, 400-499 and at least 500 cells/microl updated CD4 cell-strata were 11.6, 4.9, 2.6, 1.7, 1.5, 1.4 and 1.0, respectively. Analysis of CD4 cell count recovery permitted calculations of person-time accrued within these CD4 cell-strata. Despite rapid immune recovery, high mortality in the first year of ART was related to the large proportion of person-time accrued within CD4 cell-strata less than 200 cells/microl. Moreover, patients with baseline CD4 cell counts less than 100 cells/microl had much higher cumulative mortality estimates at 1 and 4 years (11.6 and 16.7%) compared with those of patients with baseline counts of at least 100 cells/microl (5.2 and 9.5%) largely because of greater cumulative person-time at CD4 cell counts less than 200 cells/microl. CONCLUSION: Updated CD4 cell counts are the variable most strongly associated with mortality risk during ART. High cumicrolative mortality risk is associated with person-time accrued at low CD4 cell counts. National HIV programmes in resource-limited settings should be designed to minimize the time patients spend with CD4 cell counts less than 200 cells/microl both before and during ART.
OBJECTIVE: To determine the relationship between mortality risk and the CD4 cell response to antiretroviral therapy (ART). DESIGN: Observational community-based ART cohort in South Africa. METHODS:CD4 cell counts were measured 4 monthly, and deaths were prospectively ascertained. Cumulative person-time accrued within a range of updated CD4 cell count strata (CD4 cell-strata) was calculated and used to derive CD4 cell-stratified mortality rates. RESULTS:Patients (2423) (median baseline CD4 cell count of 105 cells/microl) were observed for up to 5 years of ART. One hundred and ninety-seven patients died during 3155 person-years of observation. In microltivariate analysis, mortality rate ratios associated with 0-49, 50-99, 100-199, 200-299, 300-399, 400-499 and at least 500 cells/microl updated CD4 cell-strata were 11.6, 4.9, 2.6, 1.7, 1.5, 1.4 and 1.0, respectively. Analysis of CD4 cell count recovery permitted calculations of person-time accrued within these CD4 cell-strata. Despite rapid immune recovery, high mortality in the first year of ART was related to the large proportion of person-time accrued within CD4 cell-strata less than 200 cells/microl. Moreover, patients with baseline CD4 cell counts less than 100 cells/microl had much higher cumulative mortality estimates at 1 and 4 years (11.6 and 16.7%) compared with those of patients with baseline counts of at least 100 cells/microl (5.2 and 9.5%) largely because of greater cumulative person-time at CD4 cell counts less than 200 cells/microl. CONCLUSION: Updated CD4 cell counts are the variable most strongly associated with mortality risk during ART. High cumicrolative mortality risk is associated with person-time accrued at low CD4 cell counts. National HIV programmes in resource-limited settings should be designed to minimize the time patients spend with CD4 cell counts less than 200 cells/microl both before and during ART.
Authors: Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: Catherine Orrell; Guy Harling; Stephen D Lawn; Richard Kaplan; Matthew McNally; Linda-Gail Bekker; Robin Wood Journal: Antivir Ther Date: 2007
Authors: Robert C Kalayjian; Rhoderick N Machekano; Nesrine Rizk; Gregory K Robbins; Rajesh T Gandhi; Benigno A Rodriguez; Richard B Pollard; Michael M Lederman; Alan Landay Journal: J Infect Dis Date: 2010-06-15 Impact factor: 5.226
Authors: Brian G Williams; Reuben Granich; Kevin M De Cock; Philippe Glaziou; Abhishek Sharma; Christopher Dye Journal: Proc Natl Acad Sci U S A Date: 2010-10-25 Impact factor: 11.205
Authors: Ingrid T Katz; Thandekile Essien; Edmore T Marinda; Glenda E Gray; David R Bangsberg; Neil A Martinson; Guy De Bruyn Journal: AIDS Date: 2011-11-13 Impact factor: 4.177
Authors: Reuben Granich; Siobhan Crowley; Marco Vitoria; Ying-Ru Lo; Yves Souteyrand; Christopher Dye; Charlie Gilks; Teguest Guerma; Kevin M De Cock; Brian Williams Journal: J Int AIDS Soc Date: 2010-01-12 Impact factor: 5.396
Authors: Sabine M Hermans; Agnes N Kiragga; Petra Schaefer; Andrew Kambugu; Andy I M Hoepelman; Yukari C Manabe Journal: PLoS One Date: 2010-05-07 Impact factor: 3.240
Authors: José L Burgos; Julia A Gaebler; Steffanie A Strathdee; Remedios Lozada; Hugo Staines; Thomas L Patterson Journal: PLoS One Date: 2010-06-30 Impact factor: 3.240